Startup profile for SweetBio: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

SweetBio funding, valuation and investors

Honey-based wound care biomaterials (APIS®) for clinical healing applications.

Keep track of SweetBio

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Not publicly disclosed

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

growth · Memphis, TN

Source links not recorded Last verified: 2026-07-26

Overview

SweetBio develops medical-grade honey-incorporated wound care products (APIS) designed for clinical wound management. Based in Memphis, Tennessee, it sits in the city’s medical-device commercialization cluster.

Why SweetBio is interesting

Memphis medtech manufacturing — medical honey wound matrices from the Mid-South device corridor, not another consumer CPG honey brand.

Product & use cases

Regenerative wound care biomaterials incorporating medical honey.

  • Chronic wound management
  • Surgical wound care settings

Key facts

  • Memphis wound-care biomaterials
  • APIS honey-based matrices
  • Website: sweetbio.com

Competitive landscape

Edge: Honey-based biomaterial approach differentiated from standard collagen dressings.

  • Conventional advanced wound dressings incumbent

    Collagen/foam dressing suppliers.

Industries

Biotech & Life Sciences Healthtech

FAQs about SweetBio

Practical answers founders, operators, and investors typically search for.

Honey-based clinical wound care biomaterials.
Memphis, Tennessee.
Growth-stage private medtech.
Growth-stage private medtech.
Honey-based clinical wound care biomaterials.
Verified HQ for SweetBio; see whyInteresting.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.